LTRN241220C2000
- 0.00
- 0.000.00%
Lantern Pharma Newsroom
Express News | Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
Lantern Pharma Advances AI-Driven Cancer Therapies
Lantern Pharma Reports Q3 EPS (42c), One Estimate (56c)
Lantern Pharma | 10-Q: Q3 2024 Earnings Report
Lantern Pharma | 8-K: Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
Express News | Lantern Pharma Q3 Net Income USD -4.5 Million
Express News | Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
Earnings Preview: LTRN to Report Financial Results Post-market on November 07
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Lantern Pharma to Host & Participate in Two Public Webinars During October
Express News | Lantern Pharma Inc - Phase 1B/2a Trial for Recurrent GBM to Start Late 2024
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Express News | Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Lantern Appoints Piers Dixon as Head of Sales
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma
Express News | Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire
Express News | Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation